Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Trial frame

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    421 result(s) found for: Trial frame. Displaying page 1 of 22.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-003078-24 Sponsor Protocol Number: R668-EE-1877 Start Date*: 2020-09-01
    Sponsor Name:Regeneron Pharmaceuticals
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis
    Medical condition: Eosinophilic Esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    20.1 10017947 - Gastrointestinal disorders 10064212 Eosinophilic oesophagitis PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004445-10 Sponsor Protocol Number: CVAL489K1101 Start Date*: 2016-06-07
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Multicenter, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Valsartan in Japanese Pediatric Patients 6 to 14 Years of Age.
    Medical condition: Hypertension, Chronic Kidney Disease, Nephrotic Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002223-10 Sponsor Protocol Number: Start Date*: 2015-02-11
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: A randomised controlled trial of a new daily skincare regimen for lowering the incidence of pinsite infections following circular frame surgery
    Medical condition: Pinsite infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003583-12 Sponsor Protocol Number: CA224-047 Start Date*: 2018-05-30
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
    Medical condition: Previously Untreated Metastatic or Unresectable Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) GR (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) Outside EU/EEA IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004622-28 Sponsor Protocol Number: I5Q-MC-CGAT Start Date*: 2021-02-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study
    Medical condition: Chronic Migraine
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066636 Chronic migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Completed) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003228-54 Sponsor Protocol Number: PBF-677-3 Start Date*: 2018-05-28
    Sponsor Name:PaloBiofarma S.L.
    Full Title: A Phase IIa (proof of concept), randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety and efficacy of oral treatment with PBF-677 in patients with mild to ...
    Medical condition: Inflammatory Bowel disease, mild to moderate Ulcerative Colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003655-15 Sponsor Protocol Number: CA209-67T Start Date*: 2021-06-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carci...
    Medical condition: Metastatic Clear Cell Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002106-68 Sponsor Protocol Number: CTU/2020/354 Start Date*: 2020-07-16
    Sponsor Name:University College London Comprehensive Clinical Trial Unit
    Full Title: Favipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
    Medical condition: SARS-CoV-2 (Corona virus) infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-002204-84 Sponsor Protocol Number: I6T-MC-AMAG Start Date*: 2017-02-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects with Active Crohn’s Disease (SERENITY)
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) AT (Completed) NL (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003107-34 Sponsor Protocol Number: SHAPERON001 Start Date*: 2020-08-19
    Sponsor Name:Shaperon Inc
    Full Title: A randomized, double blind, placebo-controlled, phase 2 clinical trial to investigate the efficacy and safety of 2 doses of NuSepin® intravenous infusion in Covid-19 pneumonia patients
    Medical condition: Adult subjects with Covid-19 pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-003720-20 Sponsor Protocol Number: WI231434 Start Date*: 2019-10-16
    Sponsor Name:University of Zagreb School of Medicine
    Full Title: Varenicline Versus Cytisine for Smoking Cessation in the Primary Care Setting in Croatia and Slovenia - a Randomized Controlled Trial
    Medical condition: Tobacco addiction
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004351-23 Sponsor Protocol Number: I5Q-MC-CGAS Start Date*: 2021-02-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study
    Medical condition: Episodic Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027602 Migraine headache LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Completed) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000239-15 Sponsor Protocol Number: SFY10717 Start Date*: 2017-03-20
    Sponsor Name:Sanofi
    Full Title: An open-label, uncontrolled 4-week study to assess the safety, efficacy and pharmacokinetics of Allegra® (dry syrup formulation) 15 mg or 30 mg twice daily in pediatric patients with perennial all...
    Medical condition: Rhinitis perennial
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039094 Rhinitis perennial PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001479-22 Sponsor Protocol Number: NCT03021525 Start Date*: 2017-08-04
    Sponsor Name:University Medical Center Hamburg-Eppendorf, Germany
    Full Title: Individualized perioperative hemodynamic goal-directed therapy in major abdominal surgery (iPEGASUS-trial)
    Medical condition: - Hemodynamic Instability - Cardiac Output - High Peroperative Complication
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001387-12 Sponsor Protocol Number: CCLR325X2202 Start Date*: 2016-10-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, subject and investigator-blind, placebo-controlled study of CLR325 in chronic stable heart failure patients.
    Medical condition: Stable Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007558 Cardiac failure chronic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000238-73 Sponsor Protocol Number: CA021-002 Start Date*: 2019-01-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab...
    Medical condition: Advanced Solid Tumor
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001661-40 Sponsor Protocol Number: DE038 Start Date*: 2012-02-07
    Sponsor Name:Abbott Laboratories
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Juvenile Rheuma...
    Medical condition: Polyarticular Juvenile Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036039 Polyarticular juvenile rheumatoid arthritis, chronic or unspecified LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-001629-38 Sponsor Protocol Number: KLG0121 Start Date*: 2022-02-21
    Sponsor Name:Dompè Farmaceutici S.p.A.
    Full Title: A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two doses of DFL24412 in patients with chronic low back pain c...
    Medical condition: Chronic Low Back Pain
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10052430 Chronic lumbago LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000125-13 Sponsor Protocol Number: B3541002 Start Date*: 2017-01-12
    Sponsor Name:Pfizer Inc
    Full Title: A Multi-center, Open-label, Non-controlled Study To Evaluate The Efficacy And Safety Of Lorazepam Intravenously Administered In Subjects With Status Epilepticus Or Repetitive Status Epilepticus
    Medical condition: Status Epilepticus
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021377-36 Sponsor Protocol Number: BO22334 Start Date*: 2010-11-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: “Estudio de fase III en dos etapas, abierto, internacional, multicéntrico, aleatorizado y controlado para investigar la farmacocinética, la eficacia y la seguridad de rituximab s.c. conjuntamente c...
    Medical condition: Linfoma Folicular (LF) CD-20 psoitivo grado 1-2, 3a sin tratar previamente Previously untreated, CD20-positive follicular lymphoma (FL) grade 1-2, 3a
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061170 Follicle centre lymphoma, follicular grade I, II, III LLT
    12.1 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) BE (Completed) SK (Completed) IT (Completed) DK (Completed) DE (Completed) FR (Completed) FI (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 12:31:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA